US-based Mayo Clinic has partnered with Gentag for the development of new wearable biosensors to treat obesity and diabetes.

Gentag signed a patent pooling agreement with Mayo Clinic to manage intellectual property (IP) related to wearable patch sensor and wireless communication technologies.

As part of the deal, certain patent rights and technologies of both firms will be combined and commercialized.

Designed to be painless, wireless and disposable, the wearable patch sensors will be in the size of a small bandage and communicates through a closed-loop diabetes management system that is compatible with cell phones.

The diabetes management system will help researchers to monitor movement and develop treatments for obesity and related conditions.

The two companies will also partner with third parties under license to make available Mayo Clinic’s expertise in medicine and clinical practices to the public by the development of wearable skin patch technologies from Gentag in the areas of diabetes and obesity management.

Under the agreement, around 50 issued patents and technologies are being provided for licensing.

In addition, Mayo’s Micro-Miniature Transceiver chip will be incorporated with Gentag’s radar-responsive tag technology and integrated under license to create a new type of communication chip, which will combine Near Field Communication (NFC), Body Area Networks (BAN), as well as long-range wireless communication and geolocation.